Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.40 |
| ▸ | CDK2 | P24941 | 13/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102066 | 0.67 | PARP1 (0.35) | CCNE1CDK2PDE4APDE4BPDE4C | |
| SCHEMBL4613160 | 0.67 | PARP1 (0.35) | CCNE1CDK2PDE4APDE4BPDE4C | |
| SCHEMBL557383 | 0.65 | MAP2K1 (0.44) | CCNE1CDK2PDE4APDE4BPDE4C | |
| SCHEMBL18701563 | 0.63 | L3MBTL1 (0.40) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL22729737 | 0.63 | CCNE1 (0.55) | CCNE1CDK2PDE4APDE4BPDE4C | |
| SCHEMBL21895463 | 0.62 | XDH (0.35) | XDHCDK9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5231288 | 0.62 | ADORA2B (0.49) | CCNE1CDK2PDE4APDE4BPDE4C | |
| SCHEMBL3519381 | 0.61 | PDE3B (0.42) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL232090 | 0.60 | PNP (0.37) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8148622 | 0.60 | PDE4A (0.32) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2020057546-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | 上海迪诺医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-6914060-B2 | Imidazotriazinone derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-07-05 | — | — | US | disclosed |
| US-6914060-B2 | Imidazotriazinone derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-07-05 | — | — | US | disclosed |
| US-20040235844-A1 | Imidazotriazinone derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-11-25 | — | — | US | disclosed |
| US-20040235844-A1 | Imidazotriazinone derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235844-A1 | Imidazotriazinone derivatives as ligands for GABA receptors | GABRA2, GABRB2, GABRA4 | XDH 1537/4885CCNE1 4817/4885CDK2 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.